DK0590428T3 - Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse - Google Patents

Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse

Info

Publication number
DK0590428T3
DK0590428T3 DK93114934T DK93114934T DK0590428T3 DK 0590428 T3 DK0590428 T3 DK 0590428T3 DK 93114934 T DK93114934 T DK 93114934T DK 93114934 T DK93114934 T DK 93114934T DK 0590428 T3 DK0590428 T3 DK 0590428T3
Authority
DK
Denmark
Prior art keywords
azaquinoxalins
preparation
methods
formula
image
Prior art date
Application number
DK93114934T
Other languages
Danish (da)
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Dr Roesner
Rudolf Dr Bender
Christoph Dr Meichsner
Original Assignee
Hoechst Ag
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Aventis Pharma Gmbh filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0590428T3 publication Critical patent/DK0590428T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Radar Systems Or Details Thereof (AREA)
DK93114934T 1992-09-26 1993-09-16 Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse DK0590428T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
DK0590428T3 true DK0590428T3 (da) 2000-05-22

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93114934T DK0590428T3 (da) 1992-09-26 1993-09-16 Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse

Country Status (20)

Country Link
US (1) US5424311A (US07794700-20100914-C00152.png)
EP (1) EP0590428B1 (US07794700-20100914-C00152.png)
JP (1) JPH06211855A (US07794700-20100914-C00152.png)
KR (1) KR940007035A (US07794700-20100914-C00152.png)
AT (1) ATE187724T1 (US07794700-20100914-C00152.png)
AU (1) AU664643B2 (US07794700-20100914-C00152.png)
CA (1) CA2106882C (US07794700-20100914-C00152.png)
CZ (1) CZ9302005A3 (US07794700-20100914-C00152.png)
DE (1) DE59309902D1 (US07794700-20100914-C00152.png)
DK (1) DK0590428T3 (US07794700-20100914-C00152.png)
ES (1) ES2141744T3 (US07794700-20100914-C00152.png)
GR (1) GR3032520T3 (US07794700-20100914-C00152.png)
HU (1) HUT65302A (US07794700-20100914-C00152.png)
IL (1) IL107081A (US07794700-20100914-C00152.png)
MX (1) MX9305894A (US07794700-20100914-C00152.png)
NZ (1) NZ248762A (US07794700-20100914-C00152.png)
PH (1) PH30348A (US07794700-20100914-C00152.png)
PT (1) PT590428E (US07794700-20100914-C00152.png)
TW (1) TW274550B (US07794700-20100914-C00152.png)
ZA (1) ZA937081B (US07794700-20100914-C00152.png)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018616A2 (en) * 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6482448B2 (en) 1998-07-16 2002-11-19 Aaron Tabor Soy formulations and their use for promoting health
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MXPA05012645A (es) * 2003-05-23 2006-02-08 Zentaris Gmbh Piridopirazinas novedosas y su uso como moduladores de cinasa.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AP2408A (en) * 2006-04-21 2012-05-30 Pfizer Prod Inc Pyridine[3,4-B]pyrazinones.
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8372114B2 (en) * 2006-11-13 2013-02-12 Electroformed Stents, Inc. Over-the-wire exclusion device and system for delivery
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
MY152386A (en) * 2009-01-23 2014-09-15 Takeda Pharmaceutical Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
US8476270B2 (en) * 2009-09-14 2013-07-02 Gilead Sciences, Inc. Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors
BR112012009751A2 (pt) * 2009-10-26 2020-09-24 Signal Pharmaceuticals, Llc métodos de síntese e purificação de heteroarila
NZ601581A (en) * 2010-02-03 2014-03-28 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
TWI758746B (zh) 2011-10-19 2022-03-21 美商標誌製藥公司 以tor激酶抑制劑治療癌症
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
MY169749A (en) 2011-12-02 2019-05-15 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
TW201441227A (zh) 2013-01-16 2014-11-01 Signal Pharm Llc 經取代吡咯并嘧啶化合物、其組合物及其治療方法
BR112015026247B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
EP3848375B1 (en) 2014-09-16 2023-12-27 Gilead Sciences, Inc. Methods of preparing intermediates for toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
GR72941B (US07794700-20100914-C00152.png) * 1978-10-20 1984-01-16 Lilly Co Eli
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
PT509398E (pt) * 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao

Also Published As

Publication number Publication date
PT590428E (pt) 2000-04-28
EP0590428B1 (de) 1999-12-15
AU664643B2 (en) 1995-11-23
TW274550B (US07794700-20100914-C00152.png) 1996-04-21
AU4755393A (en) 1994-03-31
HU9302696D0 (en) 1993-12-28
HUT65302A (en) 1994-05-02
US5424311A (en) 1995-06-13
ZA937081B (en) 1994-04-18
KR940007035A (ko) 1994-04-26
CZ9302005A3 (en) 1994-04-13
PH30348A (en) 1997-04-02
EP0590428A1 (de) 1994-04-06
CA2106882A1 (en) 1994-03-27
JPH06211855A (ja) 1994-08-02
MX9305894A (es) 1994-03-31
CA2106882C (en) 2007-04-17
ATE187724T1 (de) 2000-01-15
IL107081A (en) 1999-07-14
DE59309902D1 (de) 2000-01-20
GR3032520T3 (en) 2000-05-31
NZ248762A (en) 1996-01-26
ES2141744T3 (es) 2000-04-01
IL107081A0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
DK0590428T3 (da) Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse
ATE269290T1 (de) Benzoylderivate
BG92804A (bg) 4-бензоилизоксазолови производни
ATE236886T1 (de) 2,4-dioxo-imidazolidin-derivate
ATE50763T1 (de) Tetralin-derivate, ihre herstellung und verwendung.
UA7017A1 (uk) Гербіцидний засіб
DK0519327T3 (da) N-Acyl-S-(2-hydroxyalkyl) -cysteiner, deres fremstilling samt deres anvendelse som mellemprodukter til fremstilling af synt
MX9201760A (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
FI904604A0 (fi) Pyrimidin-4,6 -dikarboxylsyraamider, foerfarande foer deras framstaellning samt deras anvaendning samt pao dessa foereningar baserade laekemedel.
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
NO930205D0 (no) Benzimidazoler, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
BG98238A (en) Substituted benzothiazole derivatives, methods for their preparation and their application as herbicides
NO20015202D0 (no) <beta>-hydroksyalkylamider, fremgangsmåte for deres fremstilling og deres anvendelse
ATE92070T1 (de) Azachromanderivate.
BR9916154A (pt) 1 3, 5 triazinas substituìdas
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
DE3767940D1 (de) Pyranderivate.
ES2054631T3 (es) 1-(2-halogeno-alcoxi-bencenosulfonil)-3-heteroaril-ureas, 3-substituidas.